InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
HomerRomer Free
12/22/20 5:16 PM
profile icon
Twinsoul Free
09/20/18 5:46 PM
profile icon
Trent Blair Free
11/19/15 3:04 AM
profile icon
JustGoLong Free
08/12/15 10:01 AM
profile icon
ronpopeil Free
05/27/15 4:18 PM
profile icon
HallaDurg Free
10/09/14 11:40 AM
profile icon
Balystyk Free
09/11/14 4:12 PM
profile icon
stocktrademan Free
09/11/14 3:13 PM
profile icon
JamieFlagg Free
09/11/14 2:27 PM
profile icon
JamieFlagg Free
09/10/14 7:53 PM
profile icon
Balystyk Free
09/10/14 7:40 PM
profile icon
JamieFlagg Free
09/09/14 11:33 PM
profile icon
JamieFlagg Free
09/04/14 10:44 PM
profile icon
JamieFlagg Free
09/03/14 4:08 PM
profile icon
JamieFlagg Free
09/03/14 11:27 AM
profile icon
HallaDurg Free
09/03/14 9:58 AM
profile icon
JamieFlagg Free
09/02/14 11:26 AM
profile icon
HallaDurg Free
08/28/14 11:22 AM

BIOYF (BIOYF) RSS Feed

Followers
7
Posters
9
Posts (Today)
0
Posts (Total)
20
Created
08/28/14
Type
Free
Moderators


BioSyent is a profitable, growth oriented specialty pharmaceutical company that sources and markets innovative products. The company acquires the exclusive rights to patented pharmaceutical products that have already been proven to be safe and effective, and then markets and distributes them in Canada. The company focuses on products with small but very profitable addressable markets ($2-15 million peak penetration) in Canada. The company's goal is to acquire and distribute two to four new products per year, thus showing consistent profitable growth.



Total sales for Q2 2014 of $3,072,395, were 72% higher compared to $1,786,684 in the corresponding prior year period. Total Sales for H1 2014 of $5,520,496 were 66% higher than H1 2013.

Pharmaceutical Sales in Q2 2014 increased by 72% from $1,683,793 in Q2 2013 to $2,893,162 in Q2 2014. Total Pharmaceutical Sales for H1 2014 of $5,236,170 were 75% higher than H1 2013.

Net Income Before Tax for Q2 2014 was $1,219,855, which was 125% higher than $542,964 in Q2 2013. Net Income Before Tax for H1 2014 was $1,907,527 or 86% higher than the corresponding prior year period.

Net Income After Tax increased by 112% from $418,325 in Q2 2013 to $888,805 in Q2 2014. Net Income After Tax for H1 2014 was $1,400,226 or 84% higher than the corresponding prior year period.

  The company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada    




BIOYF Security Details
Share Structure
Market Value $115,710,000 a/o Aug 27, 2014
Shares Outstanding 13,800,000 a/o Jun 30, 2014
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
BIOYF Latest News
  • No Recent News Available for this company!
New Post